Gradient Investments LLC Buys 3,289 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Gradient Investments LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 65.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,298 shares of the medical research company’s stock after buying an additional 3,289 shares during the quarter. Gradient Investments LLC’s holdings in Thermo Fisher Scientific were worth $2,696,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Hexavest Inc. increased its position in Thermo Fisher Scientific by 46.3% during the 4th quarter. Hexavest Inc. now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 31 shares during the period. Karp Capital Management Corp grew its position in shares of Thermo Fisher Scientific by 0.7% in the 3rd quarter. Karp Capital Management Corp now owns 4,980 shares of the medical research company’s stock worth $1,451,000 after buying an additional 35 shares during the last quarter. Brandywine Oak Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 2.0% in the 3rd quarter. Brandywine Oak Private Wealth LLC now owns 1,813 shares of the medical research company’s stock worth $528,000 after buying an additional 36 shares during the last quarter. Signet Financial Management LLC grew its position in shares of Thermo Fisher Scientific by 4.1% in the 3rd quarter. Signet Financial Management LLC now owns 937 shares of the medical research company’s stock worth $275,000 after buying an additional 37 shares during the last quarter. Finally, Landmark Bank grew its position in shares of Thermo Fisher Scientific by 0.3% in the 3rd quarter. Landmark Bank now owns 13,623 shares of the medical research company’s stock worth $3,968,000 after buying an additional 40 shares during the last quarter. Institutional investors own 88.25% of the company’s stock.

TMO has been the topic of a number of analyst reports. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Needham & Company LLC initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 3rd. They issued a “strong-buy” rating and a $271.00 price objective on the stock. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, January 6th. They issued a “buy” rating and a $380.00 price objective on the stock. Wells Fargo & Co initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, January 7th. They issued an “equal weight” rating and a $350.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Thermo Fisher Scientific in a research report on Thursday, November 14th. They issued a “buy” rating and a $345.00 price objective on the stock. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $323.27.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 47,729 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the sale, the chief executive officer now owns 328,960 shares of the company’s stock, valued at approximately $97,332,684.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.45% of the stock is currently owned by insiders.

NYSE:TMO opened at $335.20 on Thursday. The company has a market cap of $131.82 billion, a PE ratio of 30.14, a P/E/G ratio of 1.94 and a beta of 1.12. Thermo Fisher Scientific Inc. has a twelve month low of $233.71 and a twelve month high of $336.89. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average is $322.80 and its two-hundred day moving average is $297.93.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, topping the consensus estimate of $2.88 by $0.06. The company had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. Thermo Fisher Scientific’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.62 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th were given a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.23%. The ex-dividend date of this dividend was Monday, December 16th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Friday, November 8th that authorizes the company to buyback $2.50 million in outstanding shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: Why do earnings reports matter?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.